Abogen Announces Licensing

Beyond's analysis on Abogen Announces Licensing

• 2026-10-02 — Abogen’s mRNA T‑cell engager deal with Novartis expands immunotherapy pipeline and validates its RNA platform
• 2026-10-02 — Abogen licenses its mRNA-encoded T-cell engager to Novartis, expanding the latter's immuno-oncology pipeline

Recent news mentioning Abogen Announces Licensing

• 2026-10-02 — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
• 2026-10-02 — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

Appears alongside

• Novartis
• Option Agreement
• Advance
• T-Cell Engager
• RNA

Browse the full archive →